MEP2508A - Tretiranje neurotskih poremećaja - Google Patents

Tretiranje neurotskih poremećaja

Info

Publication number
MEP2508A
MEP2508A MEP-25/08A MEP2508A MEP2508A ME P2508 A MEP2508 A ME P2508A ME P2508 A MEP2508 A ME P2508A ME P2508 A MEP2508 A ME P2508A
Authority
ME
Montenegro
Prior art keywords
treatment
disorder
neurotic disorders
anxiety
neurotic
Prior art date
Application number
MEP-25/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP2508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP2508A publication Critical patent/MEP2508A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
MEP-25/08A 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja MEP2508A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Publications (1)

Publication Number Publication Date
MEP2508A true MEP2508A (xx) 2010-02-10

Family

ID=8099796

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-25/08A MEP2508A (xx) 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja
MEP-2008-25A ME00032B (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-25A ME00032B (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Country Status (38)

Country Link
US (6) US7271194B2 (fr)
EP (4) EP1440690A3 (fr)
JP (1) JP4773011B2 (fr)
KR (1) KR100604176B1 (fr)
CN (1) CN1198610C (fr)
AR (1) AR021155A1 (fr)
AT (1) ATE339955T1 (fr)
AU (6) AU782514B2 (fr)
BG (4) BG110467A (fr)
BR (1) BR0011578A (fr)
CA (4) CA2373757C (fr)
CL (3) CL2008003941A1 (fr)
CO (1) CO5190674A1 (fr)
CY (1) CY1105806T1 (fr)
CZ (1) CZ200270A3 (fr)
DE (1) DE60030861T2 (fr)
DK (1) DK1200081T3 (fr)
EA (1) EA006555B1 (fr)
ES (1) ES2272298T3 (fr)
HK (1) HK1048069B (fr)
HR (1) HRP20010820A2 (fr)
HU (1) HUP0201791A3 (fr)
IL (5) IL146131A0 (fr)
IS (1) IS6137A (fr)
ME (2) MEP2508A (fr)
MX (1) MXPA01011626A (fr)
MY (1) MY143278A (fr)
NO (4) NO329021B1 (fr)
PL (1) PL352030A1 (fr)
PT (1) PT1200081E (fr)
SI (1) SI1200081T1 (fr)
SK (1) SK82002A3 (fr)
TR (4) TR200402277T2 (fr)
TW (1) TWI232101B (fr)
UA (1) UA77645C2 (fr)
WO (1) WO2001003694A1 (fr)
YU (1) YU78701A (fr)
ZA (1) ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
CZ2003396A3 (cs) * 2000-07-21 2003-05-14 H. Lundbeck A/S Inhibitory transportu glycinu
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
HRP20031073A2 (en) 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram
AU2003237524A1 (en) * 2002-07-08 2004-01-23 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
CN100349885C (zh) * 2002-12-23 2007-11-21 H·隆德贝克有限公司 依他普仑氢溴酸盐及其制备方法
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
WO2005053796A1 (fr) * 2003-12-02 2005-06-16 B & B Beheer Nv Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (fr) 2005-10-14 2009-05-20 Lundbeck & Co As H Procedes de traitement de troubles du systeme nerveux central avec une combinaison de faible dose d'escitaloprame et de bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (fr) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (fr) 1991-04-16 1992-10-29 National Institutes Of Health Procede de traitement de la trichotillomanie et de l'onychophagie
WO1993009769A1 (fr) 1991-11-15 1993-05-27 Sepracor, Inc. Procedes et compositions a base de fluoxetine isomere s(+) pur
EP0714663A3 (fr) 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (fr) * 1995-02-10 1996-08-15 Eli Lilly And Company Procede de traitement ou de prevention de troubles psychiatriques
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
WO1997006792A1 (fr) 1995-08-16 1997-02-27 Eli Lilly And Company Potentialisation de la production de serotonine
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
ES2149734T3 (es) * 1997-11-11 2003-02-16 Lundbeck & Co As H Metodo para la preparacion de citalopram.
EP0957099B1 (fr) * 1998-04-15 2002-11-20 Pfizer Products Inc. Carboxamides hétérocycliques
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
ATE355054T1 (de) 1998-07-13 2006-03-15 Nps Pharma Inc Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
EP1096927A4 (fr) 1998-07-16 2002-09-04 Massachusetts Inst Technology Composition pour le traitement du stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
NZ514671A (en) * 1999-04-14 2003-10-31 H Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (fr) * 2000-04-24 2003-01-22 ARYx Therapeutics Substances et methodes de traitement de la depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
TR200402276T2 (tr) 2005-01-24
AU2008264182A1 (en) 2009-01-29
IL146131A (en) 2007-02-11
EP1440689A2 (fr) 2004-07-28
DK1200081T3 (da) 2006-12-27
JP4773011B2 (ja) 2011-09-14
DE60030861T2 (de) 2007-05-03
HRP20010820A2 (en) 2003-08-31
CO5190674A1 (es) 2002-08-29
KR100604176B1 (ko) 2006-07-25
EP1440690A3 (fr) 2004-08-18
AU5806100A (en) 2001-01-30
HK1048069A1 (en) 2003-03-21
NO20100334L (no) 2002-01-07
WO2001003694A1 (fr) 2001-01-18
US20020086899A1 (en) 2002-07-04
BG106279A (bg) 2002-08-30
IL170192A (en) 2010-04-29
NO329021B1 (no) 2010-07-26
BR0011578A (pt) 2002-03-26
BG110468A (en) 2010-01-29
PL352030A1 (en) 2003-07-28
ME00032B (fr) 2010-02-10
TR200200014T2 (tr) 2002-05-21
BG110466A (en) 2010-01-29
HUP0201791A3 (en) 2005-02-28
AU2005202685A1 (en) 2005-07-14
CL2008003938A1 (es) 2009-05-22
EP1200081A1 (fr) 2002-05-02
AU2005202684A1 (en) 2005-07-14
HUP0201791A2 (en) 2002-10-28
CA2687396A1 (fr) 2001-01-18
ATE339955T1 (de) 2006-10-15
NO20100333L (no) 2002-01-07
AR021155A1 (es) 2002-06-12
IS6137A (is) 2001-10-30
CL2008003941A1 (es) 2009-05-22
MXPA01011626A (es) 2002-06-04
AU782514B2 (en) 2005-08-04
US20040029958A1 (en) 2004-02-12
CZ200270A3 (cs) 2002-04-17
NO20020062D0 (no) 2002-01-07
BG110467A (en) 2010-01-29
US7271194B2 (en) 2007-09-18
CA2687392A1 (fr) 2001-01-18
YU78701A (sh) 2004-03-12
EP1440690A2 (fr) 2004-07-28
EA006555B1 (ru) 2006-02-24
US6960613B2 (en) 2005-11-01
EP1440691A3 (fr) 2004-08-25
US20040029956A1 (en) 2004-02-12
CA2373757C (fr) 2010-01-05
US20040029957A1 (en) 2004-02-12
AU2005202686B2 (en) 2009-01-15
IL170194A (en) 2010-05-31
CN1198610C (zh) 2005-04-27
US7265151B2 (en) 2007-09-04
EP1200081B1 (fr) 2006-09-20
AU2005202684B2 (en) 2009-01-15
ZA200108856B (en) 2002-12-24
AU2008264188A1 (en) 2009-05-07
IL146131A0 (en) 2002-07-25
TR200402277T2 (tr) 2005-01-24
JP2003504332A (ja) 2003-02-04
SK82002A3 (en) 2002-07-02
MY143278A (en) 2011-04-15
HK1048069B (zh) 2005-12-16
EP1440689A3 (fr) 2004-08-25
US20070276035A1 (en) 2007-11-29
CY1105806T1 (el) 2011-02-02
KR20020015346A (ko) 2002-02-27
CA2373757A1 (fr) 2001-01-18
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CN1360501A (zh) 2002-07-24
CA2687394A1 (fr) 2001-01-18
DE60030861D1 (de) 2006-11-02
TR200402275T2 (tr) 2005-03-21
IL170193A (en) 2010-04-29
ES2272298T3 (es) 2007-05-01
AU2005202686A1 (en) 2005-07-14
EA200200137A1 (ru) 2002-06-27
UA77645C2 (en) 2007-01-15
NO20100335L (no) 2002-01-07
AU2005202685B2 (en) 2009-01-15
CL2008003939A1 (es) 2009-06-05
US20050101665A1 (en) 2005-05-12
TWI232101B (en) 2005-05-11
EP1440691A2 (fr) 2004-07-28
PT1200081E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
NO20100334L (no) Behandling av nevrotiske forstyrrelser
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
WO2002053140A3 (fr) Nouvelles combinaisons medicamenteuses
NO984204D0 (no) Nye brodannete cykliske aminosyrer som farmasöytiske midler
IT1307047B1 (it) Apparecchiatura per il trattamento umidificato dell'apnea da sonno.
BR9708200A (pt) Aminoácidos cíclicos substituídos como agentes farmacéuticos
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
DK0998287T3 (da) Anvendelse af levobupivacain
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
EA200501280A1 (ru) Применение эсциталопрама для лечения приступов паники
NO20015228D0 (no) Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
WO2002074288A3 (fr) Composés chimiques
EA200001162A1 (ru) Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
EA200001058A1 (ru) Новые способы лечения нервных расстройств
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
WO1999051216A3 (fr) Preparations pharmaceutiques et leur modes d'utilisation
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA200501281A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
RU98114769A (ru) Способ повышения вестибулярной устойчивости человека
RU98114767A (ru) Способ повышения вестибулярной устойчивости человека